Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: An observational cohort study

Sung Joon Hong, Woo Jin Ko, Sun Il Kim, Byungha Chung, B. Djavan

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: The aim of this study was to identify the clinical baseline factors that affect the long-term treatment failure of benign prostatic hyperplasia (BPH). Methods: 437 men over 50 years of age with BPH were enrolled for this analysis. Patients were allocated to a medication and a surgical treatment (following medication) group. We initially examined the International Prostatic Symptom Score (IPSS), uroflow rate, prostate volume, postvoid residual volume, and the serum prostate specific antigen level as clinical baseline factors and analyzed differences between the two groups. Results: 337 patients (77.1%) were given maintenance medical treatment during follow-up, and 100 patients (22.9%) had surgical treatment following medication. Statistically significant differences were found in IPSS and prostate volume between the surgical and medication groups (IPSS: 22.6 ± 6.4 vs. 18.7 ± 5.8, prostate volume (cm3): 36.3 ± 14.4 vs. 30.1 ± 11.0, respectively). According to the ROC curve-based prediction of the failure for medical therapy, the best cutoff values of IPSS and prostate volume were 21 (area under ROC curve: 0.67) and 32 cm3 (area under ROC curve: 0.65), respectively. Conclusions: The results show that BPH patients with more severe IPSS and larger prostate volume have a higher risk of medical treatment failure, and suggest that the IPSS and prostate volume may be useful predictors of medical treatment maintenance.

Original languageEnglish
Pages (from-to)94-100
Number of pages7
JournalEuropean Urology
Volume44
Issue number1
DOIs
Publication statusPublished - 2003 Jul 1

Fingerprint

Prostatic Hyperplasia
Treatment Failure
Observational Studies
Prostate
Cohort Studies
ROC Curve
Area Under Curve
Therapeutics
Residual Volume
Prostate-Specific Antigen
Maintenance
Serum

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{cd6d9682ed334f57b81e317f1a4523db,
title = "Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: An observational cohort study",
abstract = "Objective: The aim of this study was to identify the clinical baseline factors that affect the long-term treatment failure of benign prostatic hyperplasia (BPH). Methods: 437 men over 50 years of age with BPH were enrolled for this analysis. Patients were allocated to a medication and a surgical treatment (following medication) group. We initially examined the International Prostatic Symptom Score (IPSS), uroflow rate, prostate volume, postvoid residual volume, and the serum prostate specific antigen level as clinical baseline factors and analyzed differences between the two groups. Results: 337 patients (77.1{\%}) were given maintenance medical treatment during follow-up, and 100 patients (22.9{\%}) had surgical treatment following medication. Statistically significant differences were found in IPSS and prostate volume between the surgical and medication groups (IPSS: 22.6 ± 6.4 vs. 18.7 ± 5.8, prostate volume (cm3): 36.3 ± 14.4 vs. 30.1 ± 11.0, respectively). According to the ROC curve-based prediction of the failure for medical therapy, the best cutoff values of IPSS and prostate volume were 21 (area under ROC curve: 0.67) and 32 cm3 (area under ROC curve: 0.65), respectively. Conclusions: The results show that BPH patients with more severe IPSS and larger prostate volume have a higher risk of medical treatment failure, and suggest that the IPSS and prostate volume may be useful predictors of medical treatment maintenance.",
author = "Hong, {Sung Joon} and Ko, {Woo Jin} and Kim, {Sun Il} and Byungha Chung and B. Djavan",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0302-2838(03)00199-4",
language = "English",
volume = "44",
pages = "94--100",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia : An observational cohort study. / Hong, Sung Joon; Ko, Woo Jin; Kim, Sun Il; Chung, Byungha; Djavan, B.

In: European Urology, Vol. 44, No. 1, 01.07.2003, p. 94-100.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia

T2 - An observational cohort study

AU - Hong, Sung Joon

AU - Ko, Woo Jin

AU - Kim, Sun Il

AU - Chung, Byungha

AU - Djavan, B.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective: The aim of this study was to identify the clinical baseline factors that affect the long-term treatment failure of benign prostatic hyperplasia (BPH). Methods: 437 men over 50 years of age with BPH were enrolled for this analysis. Patients were allocated to a medication and a surgical treatment (following medication) group. We initially examined the International Prostatic Symptom Score (IPSS), uroflow rate, prostate volume, postvoid residual volume, and the serum prostate specific antigen level as clinical baseline factors and analyzed differences between the two groups. Results: 337 patients (77.1%) were given maintenance medical treatment during follow-up, and 100 patients (22.9%) had surgical treatment following medication. Statistically significant differences were found in IPSS and prostate volume between the surgical and medication groups (IPSS: 22.6 ± 6.4 vs. 18.7 ± 5.8, prostate volume (cm3): 36.3 ± 14.4 vs. 30.1 ± 11.0, respectively). According to the ROC curve-based prediction of the failure for medical therapy, the best cutoff values of IPSS and prostate volume were 21 (area under ROC curve: 0.67) and 32 cm3 (area under ROC curve: 0.65), respectively. Conclusions: The results show that BPH patients with more severe IPSS and larger prostate volume have a higher risk of medical treatment failure, and suggest that the IPSS and prostate volume may be useful predictors of medical treatment maintenance.

AB - Objective: The aim of this study was to identify the clinical baseline factors that affect the long-term treatment failure of benign prostatic hyperplasia (BPH). Methods: 437 men over 50 years of age with BPH were enrolled for this analysis. Patients were allocated to a medication and a surgical treatment (following medication) group. We initially examined the International Prostatic Symptom Score (IPSS), uroflow rate, prostate volume, postvoid residual volume, and the serum prostate specific antigen level as clinical baseline factors and analyzed differences between the two groups. Results: 337 patients (77.1%) were given maintenance medical treatment during follow-up, and 100 patients (22.9%) had surgical treatment following medication. Statistically significant differences were found in IPSS and prostate volume between the surgical and medication groups (IPSS: 22.6 ± 6.4 vs. 18.7 ± 5.8, prostate volume (cm3): 36.3 ± 14.4 vs. 30.1 ± 11.0, respectively). According to the ROC curve-based prediction of the failure for medical therapy, the best cutoff values of IPSS and prostate volume were 21 (area under ROC curve: 0.67) and 32 cm3 (area under ROC curve: 0.65), respectively. Conclusions: The results show that BPH patients with more severe IPSS and larger prostate volume have a higher risk of medical treatment failure, and suggest that the IPSS and prostate volume may be useful predictors of medical treatment maintenance.

UR - http://www.scopus.com/inward/record.url?scp=0037974440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037974440&partnerID=8YFLogxK

U2 - 10.1016/S0302-2838(03)00199-4

DO - 10.1016/S0302-2838(03)00199-4

M3 - Article

C2 - 12814681

AN - SCOPUS:0037974440

VL - 44

SP - 94

EP - 100

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -